Skip to main
CELC

Celcuity (CELC) Stock Forecast & Price Target

Celcuity (CELC) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Celcuity is expected to continue its strong performance with the potential approval and commercialization of gedatolisib in advanced breast cancer, with increased market share and sales estimates. Additionally, the company's ongoing and planned operations show a strong level of preparedness and potential for international expansion. An enhanced financial model and increased probability of success for the PIK3CAmt cohort has resulted in a higher price target for the company's stock.

Bears say

Celcuity is currently facing a negative outlook due to the potential for limited efficacy of their candidate gedatolisib compared to already established treatments such as Roche's INAVO120, high operating expenses, and a potentially limited patient population for their VIKTORIA-2 trial. Despite recent data validating the importance of PIK3CA mutations, which could potentially expand eligibility in future trials, the company's current financials and the focus on dosing patients in the safety lead-inportion of the trial suggest a longer timeline for profitability.

Celcuity (CELC) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celcuity (CELC) Forecast

Analysts have given Celcuity (CELC) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Celcuity (CELC) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $131, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $131, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celcuity (CELC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.